Clinical trial
To Compare Treatment With Doxorubicin or Capecitabine for Metastatic Breast…
NCT00082095 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry · Terminated
Key facts
| NCT number | NCT00082095 |
|---|---|
| Title | To Compare Treatment With Doxorubicin or Capecitabine for Metastatic Breast Cancer in Women 60 Years and Older |
| Official title | A Randomized, Open-Label Trial Comparing Treatment With Either Pegylated Liposomal Doxorubicin or Capecitabine as First Line Chemotherapy for Metastatic Breast Cancer in Women 60 Years and Older |
| Lead sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry |
| Collaborators | Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Metastatic Breast Cancer |
| Intervention type | Drug |
| Interventions | Pegylated liposomal doxorubicin, Capecitabine |
| Enrollment | 62 |
| Start date | Apr 1, 2004 |
| Primary completion | Dec 1, 2005 |
| Completion | Dec 1, 2005 |
| First posted | Apr 30, 2004 |
| Last update posted | Oct 9, 2014 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: